Savara Inc. – NASDAQ:SVRA

Add to watchlist

$2.96

-0.18

-6.03%

Market closed

Open in about 14 hours

-35.58%

month

-35.58%

quarter

-34.38%

year

Market Cap	540.59M
Enterprise value	238.27M

P/E	-6.92
EV/Sales	N/A
EV/EBITDA	-4.48
Price/Sales	N/A
Price/Book	2.45
PEG ratio	-0.10
EPS	-0.37

Revenue	N/A
EBITDA	-69.36M
Income	-64.48M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Savara Inc. (NASDAQ:SVRA): Profit margin
Jun 2023	0	-11.44M
Sep 2023	0	-16.59M
Dec 2023	0	-16.09M
Mar 2024	0	-20.34M

Savara Financials Estimate

Q Y

Savara Inc. (NASDAQ:SVRA): Analyst Estimates
Dec 2023	0	-16.09M
Mar 2024	0	-20.34M
Sep 2025	0	-18.71M
Dec 2025	0	-21.44M

Analysts Price target
Financials & Ratios estimates

Savara Inc. (NASDAQ:SVRA): Debt to assets
Jun 2023	119833000	32.11M	26.8%
Sep 2023	182072000	35.52M	19.51%
Dec 2023	177564000	37.19M	20.95%
Mar 2024	158295000	36.43M	23.02%

Savara Inc. (NASDAQ:SVRA): Cash Flow
Jun 2023	-10.27M	-1.00M	104K
Sep 2023	-13.16M	-56.58M	74.75M
Dec 2023	-15.60M	6.57M	7.89M
Mar 2024	-20.64M	10.79M	49K

Savara alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Savara Inc. (NASDAQ:SVRA): Employee count
Aug 2023	28
Sep 2023	28
Oct 2023	28
Nov 2023	28
Dec 2023	28
Jan 2024	28
Feb 2024	28
Mar 2024	37
Apr 2024	37
May 2024	37
Jun 2024	37
Jul 2024	37

Savara
Hedge Funds Holdings Q1 2023

2.33% -50.32%

of SVRA is owned by hedge funds

30 -22

hedge funds hold SVRA stock

3.56M -76.87M

shares is hold by hedge funds

SVRA hedge funds holdings changes

Savara Inc. (NASDAQ:SVRA): Insider trades (number of shares)
Period	Buy	Sel
Nov 2024	120000	0
Dec 2024	0	87702

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	16 Dec 2024	HAWKINS RICHARD J director	Common Stock	8,000	$3.32	$26,568
Sale	16 Dec 2024	LOWRANCE DAVID L officer: Chief Fi..	Common Stock	25,000	$3.33	$83,275
Sale	16 Dec 2024	PAULS MATTHEW director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	54,702	$3.31	$180,845
Purchase	19 Nov 2024	MCCRACKEN JOSEPH S director director	Common Stock	20,000	$2.95	$59,080
Purchase	18 Nov 2024	RAMSAY DAVID A director director	Common Stock	100,000	$2.88	$287,600
Sale	28 Dec 2023	ELAM NEVAN C director	Common Stock	93,843	$4.71	$442,282
Option	28 Dec 2023	ELAM NEVAN C director	Common Stock	12,000	$1.59	$19,080
Option	28 Dec 2023	ELAM NEVAN C director	Common Stock	1,758	$0.82	$1,442
Sale	28 Dec 2023	PAULS MATTHEW director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	84,000	$4.71	$395,892
Sale	28 Dec 2023	LOWRANCE DAVID L officer: CHIEF FI..	Common Stock	10,000	$4.71	$47,130

Status	Patent	Filling date	Issue date
Application	Application DRY POWDER VANCOMYCIN COMPOSITIONS AND ASSOCIATED METHODS Filling date: 4 Jan 2021 Issue date: 27 May 2021	4 Jan 2021	27 May 2021
Application	Application DRY POWDER VANCOMYCIN COMPOSITIONS AND ASSOCIATED METHODS Filling date: 8 Jan 2020 Issue date: 21 May 2020	8 Jan 2020	21 May 2020
Application	Application SEPARATION OF VANCOMYCIN AND ITS DEGRADATION PRODUCTS Filling date: 15 Oct 2019 Issue date: 16 Apr 2020	15 Oct 2019	16 Apr 2020
Grant	Grant Utility: Dry powder Vancomycin compositions and associated methods Filling date: 9 Aug 2019 Issue date: 18 Feb 2020	9 Aug 2019	18 Feb 2020
Application	Application DRY POWDER VANCOMYCIN COMPOSITIONS AND ASSOCIATED METHODS Filling date: 9 Aug 2019 Issue date: 19 Dec 2019	9 Aug 2019	19 Dec 2019
Grant	Grant Utility: Dry powder vancomycin compositions and associated methods Filling date: 10 Dec 2015 Issue date: 24 Sep 2019	10 Dec 2015	24 Sep 2019
Grant	Grant Utility: Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties Filling date: 7 Nov 2016 Issue date: 10 Sep 2019	7 Nov 2016	10 Sep 2019

Savara
Earnings Call Transcripts

Quarter	Transcript
Q2 2020 7 Aug 2020	Q2 2020 Earnings Call Transcript
Q1 2020 7 May 2020	Q1 2020 Earnings Call Transcript
Q4 2019 13 Mar 2020	Q4 2019 Earnings Call Transcript
Q3 2019 8 Nov 2019	Q3 2019 Earnings Call Transcript

SVRA earnings call transcripts

Savara
Executives

Insider	Age	Compensation
Dr. Badrul A. Chowdhury M.D., Ph.D. (1959) Chief Medical Officer	66	$766,490
Mr. Matthew Pauls (1971) Chairman & Chief Executive Officer	54	$670,880
Mr. David L. Lowrance (1968) Chief Financial Officer & Sec.	57	$563,200

Savara
Latest News

Monday, 23 December 2024
16:05	Savara Announces New Employment Inducement Grant	businesswire.com
Wednesday, 18 December 2024
16:05	Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	businesswire.com
Tuesday, 17 December 2024
16:05	Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference	businesswire.com
Friday, 22 November 2024
16:05	Savara Announces New Employment Inducement Grant	businesswire.com
08:05	Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024	businesswire.com
Tuesday, 22 October 2024
08:05	Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV	businesswire.com
Friday, 18 October 2024
16:05	Savara Announces New Employment Inducement Grant	businesswire.com
Tuesday, 1 October 2024
08:05	Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting	businesswire.com
Friday, 27 September 2024
16:05	Savara Announces New Employment Inducement Grant	businesswire.com
08:05	Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	businesswire.com
Monday, 23 September 2024
08:05	Savara to Host Analyst and Investor Webinar on September 30, 2024	businesswire.com
Thursday, 15 August 2024
08:05	Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024	businesswire.com
Wednesday, 26 June 2024
09:36	Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?	benzinga.com
06:41	Savara's rare lung disease drug meets main goal in late-stage study	reuters.com
06:30	Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	businesswire.com
Tuesday, 25 June 2024
20:05	Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	businesswire.com
Wednesday, 19 June 2024
09:00	3 Penny Stocks Poised for Major Upside Over the Next 5 Years	investorplace.com
Tuesday, 11 June 2024
06:00	3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition	investorplace.com
Friday, 7 June 2024
05:56	Savara: The Binary Bet On Phase 3 Data	seekingalpha.com
Wednesday, 29 May 2024
08:05	Savara to Present at the Jefferies Global Healthcare Conference	businesswire.com
Sunday, 19 May 2024
12:15	Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024	businesswire.com
Thursday, 16 May 2024
16:05	Savara Announces New Employment Inducement Grant	businesswire.com
Thursday, 9 May 2024
16:05	Savara Reports First Quarter 2024 Financial Results and Provides Business Update	businesswire.com
Tuesday, 7 May 2024
16:05	Savara to Present at the Citizens JMP Life Sciences Conference	businesswire.com
Monday, 8 April 2024
08:05	Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024	Business Wire
Thursday, 1 February 2024
06:40	3 stocks to turn $100 into $1,000 in 2024	Finbold
Wednesday, 31 January 2024
08:05	Savara to Present at Two Upcoming Healthcare Conferences	Business Wire
Wednesday, 27 September 2023
19:29	3 Penny Stocks to Provide 1,000% Returns Over the Next Decade	InvestorPlace
Tuesday, 12 September 2023
09:12	The 3 Best Penny Stocks to Buy Now: September 2023	InvestorPlace
Tuesday, 5 September 2023
16:05	Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference	Business Wire

Ideas & Opinions

Seeking Alpha 21 Apr 2025

Savara: Make-It-Or-Break-It Molbreevi BLA Filing
Seeking Alpha 7 Jun 2024

Savara: The Binary Bet On Phase 3 Data
Seeking Alpha 16 Jul 2023

Savara: A Speculative Play
Seeking Alpha 7 Jun 2021

Savara: They Failed Once, But They Are Trying Again

Frequently Asked Questions (FAQ)

What's the price of Savara stock today?

One share of Savara stock can currently be purchased for approximately $2.96.
When is Savara's next earnings date?

Unfortunately, Savara's (SVRA) next earnings date is currently unknown.
Does Savara pay dividends?

No, Savara does not pay dividends.
How much money does Savara make?

Savara has a market capitalization of 540.59M.
What is Savara's stock symbol?

Savara Inc. is traded on the NASDAQ under the ticker symbol "SVRA".
What is Savara's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Savara?

Shares of Savara can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Savara's key executives?
Savara's management team includes the following people:
- Dr. Badrul A. Chowdhury M.D., Ph.D. Chief Medical Officer(age: 66, pay: $766,490)
- Mr. Matthew Pauls Chairman & Chief Executive Officer(age: 54, pay: $670,880)
- Mr. David L. Lowrance Chief Financial Officer & Sec.(age: 57, pay: $563,200)
How many employees does Savara have?

As Jul 2024, Savara employs 37 workers.
When Savara went public?

Savara Inc. is publicly traded company for more then 8 years since IPO on 28 Apr 2017.
What is Savara's official website?

The official website for Savara is savarapharma.com.
Where are Savara's headquarters?

Savara is headquartered at Building III, Austin, TX.
How can i contact Savara?

Savara's mailing address is Building III, Austin, TX and company can be reached via phone at +51 26141848.

Savara Inc.

savarapharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

+51 26141848

Building III
Austin, TX 78746

CIK: 0001160308
ISIN: US8051111016
CUSIP: 805111101